581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[131I]iodobenzmide ([131I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

Molecular Targeting Probes - Radioactive & Nonradioactive -> Novel Radiochemistry & Chelation 581

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

Session Name

New Radiochemistry Methodology

Speakers

Y. Feng

Authors

Presentation Topic

Molecular Targeting Probes - Radioactive & Nonradioactive -> Novel Radiochemistry & Chelation

Presentation Number

581

Previous Eposter

580 - Evaluation of Methods to Decrease Formation of a Higher Molecular Weight Species When²¹¹At-Labeling of Antibody-B10 Conjugates Using Chloramine-T as Oxidant (ID 1244)

Next Eposters

583 - Nucleophilic radiofluorination of aryl halides with K¹⁸F mediated by well-defined copper complexes (ID 1242)

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

586 - A general ¹¹C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

587 - MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer (ID 1246)

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

593 - Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (ID 777)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

Previous Eposter

580 - Evaluation of Methods to Decrease Formation of a Higher Molecular Weight Species When²¹¹At-Labeling of Antibody-B10 Conjugates Using Chloramine-T as Oxidant (ID 1244)

Next Eposters

583 - Nucleophilic radiofluorination of aryl halides with K¹⁸F mediated by well-defined copper complexes (ID 1242)

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

586 - A general ¹¹C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

587 - MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer (ID 1246)

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

593 - Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (ID 777)

594 - Hematotoxicity after Radioligand Therapy with ¹⁷⁷Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic ¹⁷⁷Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[131I]iodobenzmide ([131I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[131I]iodobenzmide ([131I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

Previous Eposter

580 - Evaluation of Methods to Decrease Formation of a Higher Molecular Weight Species When211At-Labeling of Antibody-B10 Conjugates Using Chloramine-T as Oxidant (ID 1244)

Next Eposters

583 - Nucleophilic radiofluorination of aryl halides with K18F mediated by well-defined copper complexes (ID 1242)

585 - 18F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

586 - A general 11C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

587 - MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer (ID 1246)

588 - 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel 177Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

593 - Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (ID 777)

594 - Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic 177Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

581 - N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[¹³¹I]iodobenzmide ([¹³¹I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments. (ID 1243)

580 - Evaluation of Methods to Decrease Formation of a Higher Molecular Weight Species When²¹¹At-Labeling of Antibody-B10 Conjugates Using Chloramine-T as Oxidant (ID 1244)

583 - Nucleophilic radiofluorination of aryl halides with K¹⁸F mediated by well-defined copper complexes (ID 1242)

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

586 - A general ¹¹C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

594 - Hematotoxicity after Radioligand Therapy with ¹⁷⁷Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic ¹⁷⁷Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)